CyberKnife Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global CyberKnife Market is projected to expand from USD 638.55 Million in 2025 to USD 1.72 billion by 2031, achieving a compound annual growth rate of 17.98%. Functioning as a robotic stereotactic radiosurgery platform, the CyberKnife System offers a non-invasive alternative to traditional surgery by delivering high-energy radiation to tumors with sub-millimeter precision. This market growth is primarily fueled by an aging population and the rising global burden of cancer, factors that necessitate efficient, patient-centric outpatient treatment solutions. As reported by the American Cancer Society in 2024, the number of new cancer diagnoses in the United States surpassed 2 million for the first time, highlighting the critical and escalating demand for advanced oncological interventions.

However, widespread adoption is significantly hindered by complicated reimbursement structures and strict prior authorization mandates that impose heavy administrative workloads on healthcare providers. These regulatory and financial hurdles frequently lead to treatment delays or denials, restricting patient access to the technology. Furthermore, these barriers often discourage smaller medical facilities from committing to the substantial capital investment required for such specialized radiosurgery equipment, as the administrative complexities make the return on investment difficult to justify.

Market Drivers

The escalating global prevalence of cancer and neoplastic diseases serves as the primary catalyst for the Global CyberKnife Market, creating an urgent need for precise, high-throughput treatment modalities. As incidence rates rise due to environmental factors and aging demographics, healthcare systems are prioritizing advanced radiosurgery platforms capable of delivering potent radiation doses with sub-millimeter accuracy. This increasing disease burden necessitates non-invasive options to manage complex cases efficiently. According to a February 2024 press release from the World Health Organization titled 'Global cancer burden growing,' more than 35 million new cancer cases are predicted for 2050, representing a 77% increase from 2022 levels, a trajectory that underscores the requirement for scalable oncological solutions that can handle higher patient volumes without compromising clinical outcomes.

Simultaneously, the market is expanding due to growing patient demand for minimally invasive radiosurgery, which offers significantly reduced recovery times and shorter hospital stays compared to traditional resection. Patients are actively seeking alternatives with superior tissue-sparing capabilities, compelling hospitals to invest in robotic delivery systems to maintain competitiveness and meet these preferences. This shift is reflected in substantial capital equipment investments within the sector. As noted by Accuray Incorporated in their August 2024 financial results, the company secured gross orders of $342.1 million for the fiscal year, a 10 percent increase driven by system placements. Additionally, the manufacturer’s full-year net revenue reached $446.6 million in 2024, illustrating the sustained adoption of this technology.

Market Challenges

Stringent prior authorization requirements and complex reimbursement frameworks constitute a significant barrier to the expansion of the Global CyberKnife Market. These administrative obstacles place a heavy operational burden on healthcare providers, often forcing them to divert clinical resources toward managing insurance approvals rather than delivering care. The unpredictability of payment models and the frequency of claim denials undermine the financial stability required to offer specialized stereotactic radiosurgery. Consequently, medical facilities, particularly smaller centers with limited capital, are discouraged from investing in high-cost robotic platforms, as the return on investment becomes difficult to justify amidst such regulatory uncertainty.

This environment of delayed access directly suppresses procedure volumes and market utilization. According to the American Society for Radiation Oncology in 2024, 92% of radiation oncologists reported that prior authorization requirements caused treatment delays for their patients, with nearly one-third indicating that these administrative barriers led patients to abandon therapy entirely. When bureaucratic inefficiencies prevent patients from accessing timely treatment, the demand for advanced interventions is artificially curtailed. This reduction in patient throughput not only hampers revenue generation for providers but also signals a high-risk landscape for new adopters, effectively stalling broader market growth.

Market Trends

The Global CyberKnife Market is experiencing a decisive shift toward hypofractionated and ultra-hypofractionated regimens, condensing therapy into fewer, high-precision sessions. Clinicians are increasingly utilizing the system’s sub-millimeter accuracy to deliver stereotactic body radiation therapy (SBRT) in one to five fractions, thereby improving patient throughput and treatment adherence. This transition is supported by strong clinical evidence validating the safety and efficacy of shortened schedules for indications such as prostate cancer. According to an Accuray Incorporated press release in October 2024 regarding a New England Journal of Medicine study, the PACE-B trial demonstrated that patients treated with SBRT achieved a 95.8 percent five-year cancer control rate, a result comparable to conventional longer regimens but delivered in just five days.

At the same time, stakeholders are prioritizing strategic partnerships to penetrate emerging economies, particularly in the Asia-Pacific region where healthcare modernization is accelerating. Manufacturers are establishing local joint ventures to navigate complex regulatory landscapes and meet the surging demand for advanced radiotherapy in countries like China. These localized strategies allow companies to bypass import barriers and price their systems competitively for regional hospitals. The success of this geographic diversification is evident in recent financial performances; according to an August 2024 Investing.com article on Accuray's earnings, the company reported that China revenue grew 27% year-over-year for fiscal 2024, underscoring the region's critical role in driving future market expansion.

Key Players Profiled in the CyberKnife Market

• Accuray Incorporated
• Varian Medical Systems Inc.
• Koninklijke Philips N.V.
• Hitachi, Ltd.
• Mevion Medical Systems
• Mitsubishi Heavy Industries, Ltd.
• RaySearch Laboratories
• Siemens Healthineers AG
• ViewRay, Inc.

Report Scope

In this report, the Global CyberKnife Market has been segmented into the following categories:

CyberKnife Market, by Application:

• Tumor
• Cancer
• Vascular malformation
• Others

CyberKnife Market, by End-use:

• Hospitals
• Outpatient facilities
• Research
• Manufacturing

CyberKnife Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CyberKnife Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.